Japan NHI Medical Device Procurement: The Complete Guide to Reimbursement, Pricing, and Market Access

Why Understanding Japan's Medical Device Procurement Matters

Japan is the world's third-largest medical device market, valued at approximately $40 to $55 billion annually depending on the source and methodology. It sits behind only the United States and the broader European Union in total market size. With a population of roughly 124 million people covered by a universal health insurance system established in 1961, Japan represents a massive, sophisticated, and highly regulated market for medical device manufacturers.

Here is the critical point that many foreign manufacturers underestimate: in Japan, nearly all medical devices used in clinical practice must be reimbursed through the National Health Insurance (NHI) system. Devices that lack NHI reimbursement listing are, as a practical matter, prohibited from routine clinical use. This is fundamentally different from the United States, where a device can be marketed after FDA clearance regardless of whether CMS has established a reimbursement code, or the EU, where individual member state payers make independent coverage decisions.

Japan's NHI system functions as a single-payer pricing mechanism that determines not just whether a device gets used, but how much hospitals receive for using it, how procurement decisions are structured, and what profit margins are available throughout the supply chain. Reimbursement planning in Japan is not a post-approval commercial exercise. It is a regulatory and strategic activity that must begin before or concurrently with PMDA regulatory approval, because the timeline from regulatory approval to reimbursement listing can determine whether your device has a viable commercial future in the country.

This guide covers the complete NHI medical device procurement ecosystem: the institutional structure, pricing mechanisms, reimbursement categories, the DPC hospital payment system, hospital-level tendering, price revision policies, requirements for foreign manufacturers, and emerging trends in 2026.

Japan's Healthcare System Overview

Universal Coverage Architecture

Japan's universal health insurance system, established in 1961, provides coverage to virtually the entire population through a multi-payer structure that is administered as a single pricing and reimbursement system. The key structural elements are:

• Employees' Health Insurance (EHI): Covers private-sector employees and their dependents, managed by the Health Insurance Societies (Kenpo) or the Japan Health Insurance Association (Kyokai Kenpo). Covers roughly 60% of the population.
• National Health Insurance (NHI): Covers self-employed individuals, retirees, farmers, and others not covered by employer-based plans. Administered by municipalities. Covers roughly 30% of the population.
• Late-Stage Elderly Healthcare System: Covers individuals aged 75 and older. Funded through a combination of premiums, tax revenue, and transfers from the other insurance systems.

Despite the multi-payer structure, all insurers reimburse according to a single national fee schedule determined by the MHLW. This means there is one price for a given procedure or device nationwide. There is no negotiating different rates with different payers as in the US system.

Patient Cost-Sharing

Patients bear a portion of medical costs through co-payments:

Patient Category	Co-Payment Rate	Monthly Cap (High-Cost Medical Expense)
Standard adults (under 70)	30%	Threshold-based cap applies
Elderly (70-74), income above threshold	30%	Threshold-based cap applies
Elderly (70-74), income below threshold	20%	Threshold-based cap applies
Late-stage elderly (75+)	10%	Per-visit cap of ~800 JPY
Low-income elderly (75+)	10%	Lower cap applies

The high-cost medical expense system caps monthly out-of-pocket spending. However, from August 2026, the MHLW is raising these caps by up to 38% for higher-income patients as part of broader fiscal sustainability measures. This change is expected to increase patient cost-awareness and may indirectly affect demand for higher-priced device-based procedures.

Key Institutions Governing Device Reimbursement

Understanding which institution does what is essential for navigating Japan's reimbursement landscape.

Institution	Role	Relevance to Device Manufacturers
MHLW (Ministry of Health, Labour and Welfare)	Oversees the entire NHI system; final authority on reimbursement prices and fee schedule revisions	Sets the national fee schedule; approves NHI prices; determines biennial revision policies
Chuikyo (Central Social Insurance Medical Council)	Advisory body to MHLW on reimbursement pricing	Evaluates pricing proposals; recommends price levels for new and existing devices; deliberates on fee schedule revisions
PMDA (Pharmaceuticals and Medical Devices Agency)	Regulatory review and approval of medical devices	Grants marketing approval (Shonin/Ninsho/Todokede); regulatory approval is a prerequisite for reimbursement listing
Medical Device Reimbursement Expert Committee	Technical evaluation of device pricing	Conducts detailed assessment of device costs, clinical value, and appropriate pricing methodology

The Chuikyo is particularly important. It meets regularly to deliberate on reimbursement matters and its recommendations are almost always adopted by the MHLW. Foreign manufacturers seeking NHI listing must understand that Chuikyo proceedings are where pricing decisions are effectively made.

NHI Medical Device Reimbursement Structure

Two Categories: STM and Non-STM

Japan's NHI system divides reimbursable medical devices into two broad categories, each with a distinct pricing and listing mechanism.

STM (Special Treatment Materials)

STM devices are individually priced and listed on the NHI fee schedule. These are typically single-use, implantable, or otherwise high-cost devices where the device itself has a distinct reimbursement price. The STM list covers approximately 200,000 product items organized into roughly 1,200 functional categories.

Examples of STM devices include:

• Orthopedic implants (artificial joints, bone plates, screws)
• Cardiovascular devices (pacemakers, stents, heart valves)
• Ophthalmic implants (intraocular lenses)
• Dialysis materials
• Surgical meshes and wound care products
• Certain diagnostic reagents

For STM devices, the manufacturer or MAH applies for a specific reimbursement price. The price is set according to one of several pricing methods (discussed below) and listed as a line item in the NHI fee schedule. Hospitals purchase the device from distributors and are reimbursed the NHI-listed price when the device is used on an insured patient.

Non-STM

Non-STM devices do not receive individual reimbursement prices. Instead, the cost of these devices is incorporated into the technical fee or procedure fee for the medical service in which they are used. This category includes:

• Diagnostic imaging equipment (CT, MRI, X-ray systems)
• Endoscopes and reusable surgical instruments
• Patient monitoring systems
• Hospital infrastructure equipment
• General consumables and low-cost supplies

For non-STM devices, the manufacturer's commercial strategy must focus on demonstrating that the device enables or improves a billable procedure, rather than securing its own reimbursement code. The hospital's procurement decision is based on whether the device improves operational efficiency, diagnostic accuracy, or clinical outcomes within the fixed procedure fee.

Pricing Methods

The NHI system employs three primary pricing methods for STM devices. The method used depends on whether comparable devices already exist and whether the device represents a genuinely new technology.

1. Comparison Method (Ihyou Shutsuryoku Hou)

The comparison method is used for the majority of device pricing decisions. It applies when a functional equivalent device already exists in the same reimbursement category.

The process works as follows:

• The device is compared to the existing device(s) in its functional category
• The standard material price of the existing category serves as the baseline
• Premiums may be granted for demonstrated clinical innovation, improved functionality, or patient benefit
• The manufacturer must provide evidence supporting any premium claim (clinical data, functional comparisons, outcomes data)

Japan's premium pricing system for devices includes several tiers. The pioneer premium (for first-in-class devices representing a novel mechanism with significant clinical utility) can add 50-100% above the standard category price. The utility premium (for devices demonstrating meaningful clinical improvement over existing alternatives) adds 5-30%. The incremental/improvement premium (for devices with documented but modest functional improvements) adds 1-20%. The Chuikyo evaluates each premium application rigorously, and manufacturers must provide strong clinical and health economic evidence to justify any premium above the standard category price.

This method tends to produce prices that cluster tightly within functional categories. A new artificial hip in the same functional category as an existing one will be priced close to the existing device, with a modest premium at best for documented improvements.

2. Cost Accounting Method (Genka Keisan Hou)

The cost accounting method is used for devices that are unique and have no directly comparable product in the existing NHI fee schedule. This is the pricing method most favorable to innovative device manufacturers because it establishes price based on actual costs plus a margin.

The price is calculated as:

Price = Cost of production (or imported price) + Selling expenses + General and administrative expenses + Operating profit + Distribution margin + Consumption tax

Each component must be documented and justified. The MHLW scrutinizes cost submissions carefully, and manufacturers should expect detailed questions about manufacturing costs, component pricing, and profit margins. The operating profit margin is subject to negotiation with the Chuikyo.

3. Foreign Reference Pricing (FRP)

Japan applies a foreign reference pricing mechanism using an unweighted average of prices in five reference countries: the United States, the United Kingdom, France, Germany, and Australia.

Key FRP rules:

• The maximum NHI price is capped at 1.25 times the unweighted average of the five reference country prices
• If the highest-priced country is more than 2.5 times the lowest-priced country, the highest-priced country is excluded from the calculation
• FRP applies primarily to devices priced using the cost accounting method
• In recent years, the practical importance of FRP has diminished as the comparison method has become the dominant pricing approach

Foreign manufacturers should be aware that FRP can create situations where the Japanese NHI price is lower than the manufacturer's price in other markets, creating downward pressure on global pricing strategies.

The Reimbursement Application Process

Reimbursement Categories for New Devices

When a manufacturer applies for NHI reimbursement listing, the device is assigned to one of several categories that determine the review pathway, timeline, and rigor of evaluation.

Category	Description	Typical Timeline	Use Case
A1	Existing functional category, product already has equivalent in category	Fastest: approximately 20 days to monthly listing	New brand of an already-reimbursed device type
A2	Existing functional category, minor specification differences	Fast: approximately 1-2 months	Device with slight variations from existing listing
B1	Existing functional category, significant specification differences	Moderate: 2-4 months	Device with meaningful differences requiring review
B2	Existing functional category, different intended use or patient population	Moderate: 3-6 months	Same device type for a new indication
B3	Tentative premium for device in existing category	Moderate: 3-6 months	Device claiming innovation premium within existing code
C1	New function category for technology that has been previously evaluated in some form	Longer: 6-12 months	Device with novel features based on evaluated technology platform
C2	New function/technology requiring entirely new classification	Longest: 12-18 months	Genuinely novel device with no precedent in NHI system

Application Process Steps

The reimbursement application process for a C-category device (the most common path for foreign manufacturers with new technology) follows these stages:

1. Pre-application consultation: The manufacturer or MAH meets with the MHLW Insurance Bureau to discuss the appropriate reimbursement category and pricing method. This should occur during or before regulatory approval.

2. Application submission: The manufacturer submits a formal reimbursement application to the MHLW, including clinical data, cost data, foreign pricing information, and justification for the requested price.

3. Expert Committee review: The Medical Device Reimbursement Expert Committee evaluates the submission. For C2 devices, this includes detailed clinical and economic assessment.

4. Chuikyo deliberation: The Chuikyo reviews the Expert Committee's recommendation and deliberates on the price. Manufacturer representatives may be invited to present.

5. MHLW decision and listing: The MHLW issues the final pricing decision and the device is added to the NHI fee schedule. New listings are typically effective from the first day of the following month.

6. Publication: The new price and category listing are published in the official gazette and incorporated into the NHI fee schedule database.

Timing Considerations

The interval between PMDA regulatory approval and NHI reimbursement listing is commercially critical. Key timing facts:

• For A-category devices: listing can occur as quickly as 20 days after regulatory approval
• For C-category devices: the process typically takes 6 to 18 months after regulatory approval
• Reimbursement planning should begin before or during the PMDA approval process, not after
• Manufacturers who wait until regulatory approval is granted to begin reimbursement planning may face 12 to 18 months of commercial dead time in Japan

The DPC System and Its Impact on Device Procurement

What Is DPC?

The Diagnosis Procedure Combination (DPC) system is Japan's version of a Diagnosis-Related Group (DRG) payment model. Introduced in 2003, it is a fixed per-diem payment system for inpatient hospital care that has fundamentally altered how hospitals in Japan evaluate and purchase medical devices.

Under DPC, hospitals receive a predetermined daily payment for each inpatient, based on the patient's primary diagnosis classification, rather than being reimbursed for each individual service and device separately. The DPC system classifies inpatient cases into approximately 4,500 diagnostic groups based on roughly 500 diseases organized across 18 Major Diagnostic Categories.

DPC Coverage and Scope

As of 2026, DPC covers approximately 55% of all general hospital beds in Japan. The system has expanded steadily since its introduction and now includes most large hospitals and academic medical centers. Hospitals participating in DPC are typically those with 200 or more beds, though smaller hospitals have been gradually incorporated.

The DPC per-diem payment formula:

DPC Payment = DPC base rate x Diagnosis group coefficient x Hospital-specific coefficient x Number of days

The diagnosis group coefficient reflects the resource intensity of treating that condition. The hospital-specific coefficient reflects the hospital's teaching status, case mix, and other factors.

Impact on Device Procurement Decisions

The DPC system creates a powerful economic incentive for hospitals to control device costs. Because the hospital receives a fixed per-diem payment regardless of which specific devices are used, any cost savings from using a lower-priced device flow directly to the hospital as retained revenue.

This creates several important dynamics for device manufacturers:

• Price sensitivity is heightened: Hospitals have a direct financial incentive to choose the lowest-cost device within a functional category. A 10% price difference between two equivalent devices translates directly to hospital margin.

• Biosimilar and generic device preference: In DPC hospitals, biosimilars and lower-cost alternatives are preferred for inpatient use because the cost savings accrue to the hospital. This is one reason why biosimilar adoption has accelerated in Japanese hospitals.

• Innovation premium is harder to justify: A device that costs more must demonstrate clear clinical value that reduces length of stay, complications, or readmissions to offset its higher price within the fixed DPC payment.

• Device costs are bundled: Under DPC, individual device reimbursement is often absorbed into the per-diem payment rather than being separately billable. This means hospitals must absorb device costs from their fixed DPC revenue.

• Outpatient procedures are different: Procedures performed on an outpatient basis fall outside the DPC system and are reimbursed on a fee-for-service basis. For some device types, outpatient use represents a more favorable reimbursement environment.

Strategic Implications for Manufacturers

Device manufacturers targeting the Japanese market should analyze whether their primary use case is inpatient or outpatient:

• Inpatient (DPC-covered): Focus on demonstrating total cost of care savings, reduced length of stay, and fewer complications. Price competitiveness is paramount.
• Outpatient (fee-for-service): Focus on clinical differentiation, procedural efficiency, and physician preference. Premium pricing is more achievable.

Hospital-Level Procurement and Tendering

How Japanese Hospitals Buy Devices

Individual hospitals in Japan procure medical devices through a network of distributors and the Marketing Authorization Holder (MAH). The procurement process varies depending on whether the hospital is public or private.

Private Hospital Procurement

Most private hospitals in Japan procure devices through established relationships with distributors. The process is typically:

1. The hospital's procurement committee or department head identifies the need for a device
2. The hospital requests quotations from one or more distributors
3. The distributor provides pricing based on the NHI reimbursement price minus the hospital's expected margin
4. The hospital selects the supplier based on price, relationship, and clinical preference

The economic structure works as follows: the hospital is reimbursed the NHI-listed price for the device. The hospital purchases the device from the distributor at a discount to the NHI price. The difference between the NHI reimbursement and the purchase price is the hospital's margin on the device. This margin is a significant factor in hospital purchasing decisions.

Public Hospital Procurement

Public hospitals, including the approximately 140+ hospitals in the National Hospital Organization (NHO), are subject to government procurement rules covered by the WTO Agreement on Government Procurement (GPA). These hospitals must follow a formal tendering process for device purchases above certain thresholds.

The tender process for public hospitals follows this sequence:

1. Notice publication: The hospital publishes a procurement notice specifying the device category, quantity, and requirements
2. Explanatory meeting: A meeting is held for prospective bidders to ask questions about the requirements
3. Expression of interest: Suppliers submit expressions of interest to participate
4. Bidding documents: Qualified suppliers receive the formal bidding documents
5. Bid submission: Suppliers submit sealed bids with pricing
6. Result announcement: The hospital announces the winning bidder
7. Contract execution: The contract is finalized with the winning supplier

The JETRO (Japan External Trade Organization) Procurement Portal lists government procurement opportunities, including medical device tenders from public hospitals. This is the primary resource for foreign suppliers seeking to identify public hospital procurement opportunities.

The "Projected Price" Mechanism

Japanese hospital tenders often use a "projected price" (yotei kakaku) mechanism. Under this system, the hospital sets a target price based on previous purchase prices, NHI reimbursement levels, and budget constraints. The lowest bid that meets the technical requirements typically wins. This creates intense price competition among suppliers and further compresses margins for device manufacturers.

Impact of the EU-Japan Economic Partnership Agreement

The EU-Japan Economic Partnership Agreement (EPA), which entered into force in 2019, opened access to government procurement at more than 100 additional hospitals that were previously excluded from international tendering. This has created new opportunities for European device manufacturers to compete for public hospital contracts in Japan.

For non-EU foreign manufacturers, the EPA does not provide direct benefits, but the general trend toward greater transparency in hospital procurement creates opportunities for all foreign suppliers who establish effective Japanese distribution networks.

Pricing, Price Revisions, and Cost Containment

The Biennial Price Revision System

Japan operates a systematic price revision mechanism for NHI-reimbursed medical devices. Revisions occur biennially (every two years) for devices, though pharmaceutical revisions have moved to an annual cycle. The purpose of revisions is to adjust NHI prices downward to reflect actual market transaction prices, which typically drift below the official NHI-listed price over time.

The revision process:

1. Market price survey: The MHLW conducts a comprehensive survey of actual transaction prices between manufacturers/distributors and hospitals
2. Price gap analysis: The MHLW calculates the gap between the NHI-listed price and the actual weighted-average market price
3. Downward adjustment: The NHI price is adjusted downward toward the actual market price, typically with a "reasonable zone" that prevents excessive reductions
4. Chuikyo deliberation: The Chuikyo reviews the proposed revisions and recommends final adjustment levels
5. Implementation: Revised prices take effect, typically from April of the revision year

FY2026 Reimbursement Revisions

The FY2026 NHI fee schedule revision is currently under deliberation by the Chuikyo. Key aspects:

• Aggregate drug price reduction: NHI drug prices were reduced by an aggregate 0.86%, generating approximately 105 billion JPY in savings
• Device revisions: Device price revisions follow the biennial cycle and are being discussed as part of the FY2026 process
• Industry pushback: Industry groups including JPMA (Japan Pharmaceutical Manufacturers Association), PhRMA, and EFPIA (European Federation of Pharmaceutical Industries and Associations) have pushed back against frequent price cuts during the patent period, arguing that they undermine the incentive for innovation
• Inflation-linked adjustments: Industry is requesting that the revision system incorporate inflation-linked reimbursement adjustments, particularly for devices whose manufacturing costs have increased due to raw material and energy price inflation

Long-Term Price Trajectory

The cumulative effect of biennial price revisions is significant. A device that enters the Japanese market at a premium price can expect to see its NHI reimbursement price reduced by 20-40% or more over a decade through successive revisions. This has major implications for long-term commercial planning and must be factored into market entry financial models.

Health Technology Assessment (HTA)

Japan formally introduced HTA-based cost-effectiveness evaluations for medical products in April 2019. The Center for Outcomes Research and Economic Evaluation for Health (C2H), established under the National Institute of Public Health, conducts these assessments. While HTA initially applied primarily to pharmaceuticals, its scope has been expanding to include high-cost medical devices. Manufacturers of innovative devices priced significantly above existing alternatives should be prepared to submit health economic data as part of their reimbursement application, particularly when applying under the C2 category. The FY2026 reform discussions include proposals to further integrate cost-effectiveness criteria into device pricing decisions.

Advanced Medicine (Senshin Iryo) Pathway

For devices that have received regulatory approval but have not yet obtained NHI reimbursement listing, Japan provides an important exception pathway called Advanced Medicine (Senshin Iryo). Under this system, hospitals can apply to the government to use a non-reimbursed device under a special designation where the NHI covers associated care costs while the patient pays for the device itself. This pathway serves as a bridge for innovative devices between regulatory approval and full reimbursement listing, and it provides a mechanism for manufacturers to generate clinical evidence and build physician familiarity while pursuing NHI listing through the standard C1/C2 process.

Requirements for Foreign Medical Device Manufacturers

Regulatory Requirements

Foreign medical device manufacturers seeking to sell devices in Japan must satisfy several regulatory requirements before they can even begin the reimbursement process.

PMDA Approval

All medical devices marketed in Japan must have PMDA regulatory approval (or notification/certification for lower-risk devices). The three pathways are:

Pathway	Applicable Devices	Reviewing Body
Todokede (Notification)	Class I devices	PMDA (self-declaration)
Ninsho (Certification)	Class II and some Class III devices with certification standards	Registered Certification Bodies (RCBs)
Shonin (Approval)	Class III (without certification standard) and all Class IV devices	PMDA review, MHLW approval

From April 1, 2026, the PMDA mandates eCTD v4.0 format for all new medical device applications. This is a significant change from the previous eCTD v3.2.2 format and requires manufacturers to update their submission preparation processes.

Additionally, from May 2026, the conditional approval pathway is being expanded to cover more device types and IVDs, enabling earlier market access for devices addressing unmet medical needs, subject to post-market data collection requirements.

MAH/DMAH Requirement

Foreign manufacturers without a physical presence in Japan must designate a Domestic Marketing Authorization Holder (DMAH) or establish a Japanese subsidiary as the Marketing Authorization Holder (MAH). The MAH/DMAH is the entity that holds the marketing authorization, manages post-market obligations, and interacts with the PMDA and MHLW.

Key MAH/DMAH considerations:

• The MAH/DMAH bears regulatory responsibility for the device in Japan
• The MAH/DMAH must maintain a QMS-compliant quality management system
• The MAH/DMAH manages adverse event reporting and recall obligations
• Selecting the right MAH/DMAH partner is one of the most important strategic decisions for market entry

QMS Compliance: MHLW Ordinance No. 169

Japan requires compliance with MHLW Ministerial Ordinance No. 169, "Standards for Manufacturing Control and Quality Control of Medical Devices and In Vitro Diagnostics." While Ordinance No. 169 is harmonized with ISO 13485 in many respects, it is not identical. Foreign manufacturers who assume that ISO 13485 certification alone is sufficient will encounter problems.

Key differences from ISO 13485 include:

• Specific requirements for MAH/DMAH quality management responsibilities
• Detailed post-market surveillance and reporting obligations
• Unique design control documentation requirements aligned with Japanese regulatory expectations
• Specific provisions for manufacturing site changes and process transfers

Foreign Manufacturer Registration (FMR)

All foreign manufacturing sites that produce medical devices for the Japanese market must register with the PMDA through the Foreign Manufacturer Registration (FMR) system. This requires:

• Submission of manufacturing site information and documentation
• PMDA review and potential on-site inspection
• Registration renewal on a periodic basis
• All submitted documentation must be in Japanese

Language Requirements

All regulatory submissions, QMS documentation, labeling, and reimbursement applications must be provided in Japanese. This is a non-negotiable requirement that applies throughout the product lifecycle. Foreign manufacturers should budget for professional Japanese translation and regulatory consulting as a core cost of market entry.

Parallel Regulatory and Reimbursement Planning

The most critical strategic point for foreign manufacturers: reimbursement planning should begin before or during the PMDA regulatory approval process, not after approval is granted. The reason is simple:

• PMDA approval takes 6 to 18 months depending on the device class and pathway
• Reimbursement listing for C-category devices takes an additional 6 to 18 months
• If reimbursement planning only begins after regulatory approval, total time to commercial revenue can be 12 to 36 months after regulatory clearance

By beginning reimbursement planning during the regulatory process, manufacturers can submit the reimbursement application shortly after approval is granted, reducing the gap between regulatory clearance and commercial availability to as little as a few months for A-category devices.

Strategic Recommendations for Market Entry

Build Reimbursement Into Your Japan Strategy From Day One

Reimbursement is not a commercial afterthought in Japan. It is a core regulatory and strategic function that should be addressed from the earliest stages of Japan market planning. Specific recommendations:

• Engage a Japanese regulatory and reimbursement consultant before submitting your PMDA application. A consultant who understands both the regulatory pathway and the reimbursement landscape can help you position your device for optimal pricing.
• Map your device to existing NHI categories early. If your device fits an existing functional category, the reimbursement pathway is faster and more predictable. If it requires a new category (C2), budget additional time and resources.
• Prepare cost accounting data during product development. If your device is novel enough to warrant the cost accounting pricing method, you will need detailed manufacturing cost data. Collecting this retroactively is difficult and time-consuming.

Choose the Right MAH/DMAH Partner

The MAH/DMAH is your representative in Japan for all regulatory and commercial matters. Criteria for selection should include:

• Regulatory affairs expertise and track record with your device type
• Reimbursement expertise and relationships with the MHLW and Chuikyo
• Distribution network and hospital relationships
• Post-market surveillance capabilities
• Financial stability and organizational depth
• Willingness to invest in your product's success, not just process paperwork

Understand the DPC Dynamics for Your Device

Analyze whether your device's primary clinical use is inpatient or outpatient. This determination has profound implications for pricing strategy, hospital purchasing behavior, and commercial messaging:

• For inpatient (DPC-covered) use: emphasize total cost of care reduction, shorter length of stay, and fewer complications
• For outpatient (fee-for-service) use: emphasize clinical differentiation, procedural advantages, and physician preference

Model Long-Term Price Erosion

Factor biennial price revisions into your financial model for the Japanese market. A device launched at a premium price today will see that price reduced through successive revisions. Your commercial model should account for:

• Initial NHI price and margin structure
• Expected price reductions every two years
• Volume growth needed to offset price erosion
• The possibility that cost inflation may further compress margins

Prepare for eCTD v4.0

The April 2026 mandate for eCTD v4.0 format affects all new medical device applications to the PMDA. If your team has only worked with eCTD v3.2.2, you will need to invest in training and potentially new publishing tools. Do not let submission format become a source of delay.

Emerging Trends in 2026

Expanded Conditional Approval Pathway

From May 2026, the conditional approval pathway is being expanded to cover a broader range of devices and IVDs. This pathway allows devices addressing unmet medical needs to receive earlier market access, conditional on post-market data collection to confirm safety and efficacy. For manufacturers of innovative devices, this represents an opportunity to reduce time to market, though it comes with additional post-market obligations.

eCTD v4.0 Mandate

The PMDA's mandate for eCTD v4.0 format for all new applications from April 1, 2026, represents a significant technical change. Manufacturers should ensure their regulatory publishing systems and processes are updated to support the new format. The transition affects not just new submissions but also variations and renewals.

FY2026 Reimbursement Revisions

The biennial reimbursement revision for medical devices is under deliberation. Key areas to watch include:

• The magnitude of downward price adjustments based on market price surveys
• Whether inflation-linked adjustments will be incorporated (as industry has requested)
• Any changes to the foreign reference pricing methodology
• Adjustments to the DPC system that may affect device bundling

Increased MHLW Budget for Regulatory Capacity

The MHLW's FY2025 budget was increased by more than $3 billion, with a portion allocated to strengthening regulatory review capacity. This investment is expected to support faster PMDA review times and more efficient processing of reimbursement applications, which could reduce time to market for new devices.

High-Cost Medical Expense Cap Increases

From August 2026, monthly caps on high-cost medical expenses will increase by up to 38% for higher-income patients. This change reflects broader efforts to manage the fiscal sustainability of the NHI system in the face of Japan's aging population. For device manufacturers, the implication is that patient cost-sharing for expensive procedures may increase, potentially affecting demand for elective procedures that use high-cost devices.

Industry Advocacy on Pricing

Industry groups continue to advocate for reforms to the price revision system, including:

• Less frequent price reductions during the patent/exclusivity period
• Greater recognition of innovation value in pricing decisions
• Inflation-linked adjustments to prevent margin compression
• More transparent and predictable revision methodology

The outcome of these advocacy efforts will shape the commercial environment for medical devices in Japan over the coming years.

Practical Checklist

Use this checklist to track your progress toward NHI reimbursement and market access in Japan:

Regulatory Foundation

• Determine device classification under the JMDN system
• Identify the appropriate regulatory pathway (Todokede, Ninsho, or Shonin)
• Engage PMDA pre-submission consultation
• Designate or establish MAH/DMAH
• Complete Foreign Manufacturer Registration (FMR) for all manufacturing sites
• Achieve QMS compliance with MHLW Ordinance No. 169
• Prepare regulatory submission in eCTD v4.0 format
• Obtain PMDA approval/certification/notification

Reimbursement Planning

• Map device to existing NHI functional categories
• Determine likely reimbursement category (A1, A2, B1, B2, B3, C1, or C2)
• Identify applicable pricing method (comparison, cost accounting, or FRP)
• Collect foreign reference pricing data (US, UK, France, Germany, Australia)
• Prepare cost accounting documentation (if applicable)
• Engage MHLW pre-application consultation for reimbursement
• Submit reimbursement application to MHLW
• Support Expert Committee and Chuikyo review process

Commercial Preparation

• Analyze inpatient (DPC) vs. outpatient (fee-for-service) usage patterns
• Develop hospital value proposition aligned with DPC dynamics
• Establish distribution network or direct sales capability
• Register on JETRO Procurement Portal for public hospital tenders
• Prepare Japanese-language product documentation and labeling
• Build financial model incorporating biennial price revisions
• Train commercial team on NHI reimbursement structure and hospital economics

Key Takeaways

1. NHI reimbursement is mandatory for clinical use. Unlike the US or EU, devices without NHI listing cannot be routinely used in Japanese clinical practice. Reimbursement is a prerequisite for commercial viability, not a post-launch optimization.

2. Start reimbursement planning before regulatory approval. The gap between PMDA approval and NHI listing can be 6 to 18 months for novel devices. Parallel planning reduces this gap and accelerates time to revenue.

3. Understand STM vs. non-STM. Whether your device is individually priced (STM) or bundled into a procedure fee (non-STM) fundamentally changes your commercial strategy and pricing approach.

4. The DPC system drives cost-conscious procurement. With 55% of hospital beds under DPC, hospitals have a direct financial incentive to minimize device costs. Demonstrating total cost of care savings is essential for premium-priced devices in the inpatient setting.

5. Price erosion is systematic and predictable. Biennial price revisions will reduce your NHI price over time. Build this into your financial model from the start and plan for volume growth to offset price declines.

6. Foreign reference pricing adds complexity. Your Japanese price will be influenced by your prices in the US, UK, France, Germany, and Australia. Coordinate your global pricing strategy accordingly.

7. The MAH/DMAH decision is strategic. Your MAH/DMAH partner is your regulatory representative, commercial partner, and post-market compliance officer in Japan. Choose carefully.

8. Japanese language requirements are non-negotiable. Budget for professional translation and local regulatory expertise throughout the product lifecycle.

9. 2026 brings significant changes. eCTD v4.0, expanded conditional approval, reimbursement revisions, and high-cost medical expense cap increases all affect market access strategy this year.

10. Japan rewards preparation. The manufacturers who succeed in Japan are those who invest early in understanding the system, building the right partnerships, and planning regulatory and reimbursement pathways in parallel. The market is large and lucrative for those who get it right, but unforgiving for those who underestimate its complexity.